{"id":"W2056723407","doi":"10.1007/s10637-008-9143-2","title":"O-Mel-Inib: A Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose Imatinib mesylate in metastatic uveal melanoma","year":2008,"lang":"fr","type":"article","venue":"Investigational New Drugs","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Mashhad University of Medical Sciences","keywords":"Medicine; Imatinib mesylate; Adverse effect; Phases of clinical research; Clinical trial; Melanoma; Internal medicine; Imatinib; Surgery; Oncology; Gastroenterology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001532279,0.0009052611,0.001318477,0.0003910664,0.0004358615,0.001282362,0.0006215755,0.0009294535,0.002976081],"category_scores_gemma":[0.0007564995,0.000318116,0.0008689695,0.0003495442,0.0006724817,0.0007971259,0.0004015243,0.002342496,0.000530728],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001071376,"about_ca_system_score_gemma":0.001339871,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002407223,"about_ca_topic_score_gemma":0.01140443,"domain_scores_codex":[0.9996898,0.0001385615,0.000009870158,0.00003783366,0.00002526392,0.00009863106],"domain_scores_gemma":[0.9994953,0.00007565739,0.00006217403,0.00002246196,0.00002229275,0.0003221155],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6769642,0.03998912,0.01291285,0.001240448,0.001763452,0.0006550428,0.0004979821,0.005796002,0.05535464,0.001458772,0.02411406,0.1792535],"study_design_scores_gemma":[0.8065856,0.1439958,0.02507978,0.0001446607,0.0009699442,0.0007329703,0.0002649362,0.003135635,0.004469988,0.0008859457,0.01366666,0.0000680907],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.987298,0.004791189,0.0002882956,0.001558469,0.0002696864,0.0006397364,0.001191553,0.00008219858,0.003880888],"genre_scores_gemma":[0.9814633,0.004392017,0.001785047,0.0013446,0.0002471138,0.0007911861,0.003418049,0.00004966021,0.006509081],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002976081,"threshold_uncertainty_score":0.009956002,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04069337693991506,"score_gpt":0.3313887372190749,"score_spread":0.2906953602791599,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}